Sheila M Fleming

List of Publications by Year
in descending order

53 papers	5,330 citations	159585 30 h-index	197818 49 g-index
55 all docs	55 docs citations	55 times ranked	6910 citing authors

#	Article	IF	Citations
1	Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. Neuropharmacology, 2022, 202, 108870.	4.1	14
2	Farey Trees Explain Sequential Effects in Choice Response Time. Frontiers in Physiology, 2021, 12, 611145.	2.8	2
3	Irisin treatment lowers levels of phosphorylated tau in the hippocampus of preâ€symptomatic female but not male htau mice. Neuropathology and Applied Neurobiology, 2021, 47, 967-978.	3.2	10
4	Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration. FASEB Journal, 2020, 34, 1679-1694.	0.5	66
5	Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of Î±-synuclein-preformed fibril-induced toxicity and motor deficits. Neurobiology of Disease, 2020, 141, 104947.	4.4	24
6	Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal Î±-synuclein preformed fibrils. Neurobiology of Disease, 2019, 130, 104525.	4.4	67
7	Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein. Behavioural Brain Research, 2018, 343, 41-49.	2.2	17
8	Ahr and Cyp1a2 genotypes both affect susceptibility to motor deficits following gestational and lactational exposure to polychlorinated biphenyls. NeuroToxicology, 2018, 65, 125-134.	3.0	11
9	The effect of manganese exposure in Atp13a2-deficient mice. NeuroToxicology, 2018, 64, 256-266.	3.0	21
10	Mechanisms of Gene-Environment Interactions in Parkinsonâ€™s Disease. Current Environmental Health Reports, 2017, 4, 192-199.	6.7	74
11	Intranasal <scp>NAP</scp> (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing Î±â€synuclein. Pharmacology Research and Perspectives, 2014, 2, e00065.	2.4	40
12	Ribosomal s15: A novel therapeutic target for Parkinson's disease. Movement Disorders, 2014, 29, 990-990.	3.9	0
13	Cinnamon in a mouse model of PD. Movement Disorders, 2014, 29, 1466-1466.	3.9	5
14	A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy. Neurotherapeutics, 2014, 11, 840-856.	4.4	88
15	Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons. Neurobiology of Disease, 2014, 69, 263-275.	4.4	28
16	Olfactory Assays for Mouse Models of Neurodegenerative Disease. Journal of Visualized Experiments, 2014, , e51804.	0.3	64
17	Impaired Baroreflex Function in Mice Overexpressing Alpha-Synuclein. Frontiers in Neurology, 2013, 4, 103.	2.4	20
18	Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited Î±-synuclein accumulation and age-dependent sensorimotor deficits. Human Molecular Genetics, 2013, 22, 2067-2082.	2.9	124

#	Article	IF	Citations
19	Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease. Journal of Visualized Experiments, 2013, , .	0.3	115
20	Morphological and Behavioral Impact of AAV2/5-Mediated Overexpression of Human Wildtype Alpha-Synuclein in the Rat Nigrostriatal System. PLoS ONE, 2013, 8, e81426.	2.5	70
21	Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease. Behavioural Brain Research, 2012, 230, 309-316.	2.2	108
22	Cranial and related sensorimotor impairments in rodent models of Parkinson's disease. Behavioural Brain Research, 2012, 231, 317-322.	2.2	21
23	Cognitive deficits in a mouse model of preâ€manifest Parkinsonâ€™s disease. European Journal of Neuroscience, 2012, 35, 870-882.	2.6	87
24	Cardiovascular Autonomic Dysfunction in Animal Models of Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 321-327.	2.8	11
25	A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Molecular and Cellular Neurosciences, 2011, 46, 597-606.	2.2	68
26	HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease. Nature Neuroscience, 2011, 14, 85-92.	14.8	160
27	Comparing Behavioral Assessment of Sensorimotor Function in Rat and Mouse Models of Parkinsonâ€™s Disease and Stroke. Neuromethods, 2011, , 325-335.	0.3	0
28	Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Molecular Neurodegeneration, 2011, 6, 83.	10.8	30
29	Cognitive Dysfunction in Genetic Mouse Models of Parkinsonism. Neuromethods, 2011, , 485-492.	0.3	2
30	Mice overexpressing corticotropin-releasing factor show brain atrophy and motor dysfunctions. Neuroscience Letters, 2010, 473, 11-15.	2.1	17
31	Behavioral Outcome Measures for the Assessment of Sensorimotor Function in Animal Models of Movement Disorders. International Review of Neurobiology, 2009, 89, 57-65.	2.0	17
32	Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11125-11130.	7.1	49
33	Bacterial Artificial Chromosome Transgenic Mice Expressing a Truncated Mutant Parkin Exhibit Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Degeneration, and Accumulation of Proteinase K-Resistant Î±-Synuclein. Journal of Neuroscience, 2009, 29, 1962-1976.	3.6	168
34	Modeling Nonmotor Symptoms of Parkinsonâ€™s Disease in Genetic Mouse Models. Advances in Behavioral Biology, 2009, , 483-491.	0.2	3
35	Olfactory deficits in mice overexpressing human wildtype Î±â€synuclein. European Journal of Neuroscience, 2008, 28, 247-256.	2.6	182
36	Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice. Food and Chemical Toxicology, 2008, 46, 1371-1377.	3.6	30

#	Article	IF	Citations
37	Abnormal colonic motility in mice overexpressing human wild-type Î±-synuclein. NeuroReport, 2008, 19, 873-876.	1.2	110
38	Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behavioural Pharmacology, 2006, 17, 383-391.	1.7	59
39	Phenotypical Characterization of Genetic Mouse Models of Parkinson Disease. , 2005, , 183-192.		4
40	3,4-Dihydroxyphenylalanine Reverses the Motor Deficits in Pitx3-Deficient Aphakia Mice: Behavioral Characterization of a Novel Genetic Model of Parkinson's Disease. Journal of Neuroscience, 2005, 25, 2132-2137.	3.6	162
41	An intermittent, controlled-rate, slow progressive degeneration model of Parkinsonâ€™s disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Behavioural Brain Research, 2005, 156, 201-213.	2.2	57
42	Genetic mouse models of parkinsonism: Strengths and limitations. NeuroRx, 2005, 2, 495-503.	6.0	150
43	Early Behavioral Phenotypes in Mouse Models of Huntingtonâ€™s and Parkinsonâ€™s Diseases. , 2005, , 349-359.		0
44	Variable effects of chronic subcutaneous administration of rotenone on striatal histology. Journal of Comparative Neurology, 2004, 478, 418-426.	1.6	86
45	Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human Â-Synuclein. Journal of Neuroscience, 2004, 24, 9434-9440.	3.6	428
46	Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Experimental Neurology, 2004, 187, 418-429.	4.1	179
47	Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends in Neurosciences, 2004, 27, 691-697.	8.6	170
48	Should the injured and intact hemispheres be treated differently during the early phases of physical restorative therapy in experimental stroke or parkinsonism?. Physical Medicine and Rehabilitation Clinics of North America, 2003, 14, S27-S46.	1.3	36
49	Experimental Focal Ischemic Injury: Behavior-Brain Interactions and Issues of Animal Handling and Housing. ILAR Journal, 2003, 44, 130-143.	1.8	34
50	Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons. Journal of Biological Chemistry, 2003, 278, 43628-43635.	3.4	784
51	CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 2000, 39, 777-787.	4.1	1,217
52	Prefrontal cortex infusions of SCH 23390 cause immediate and delayed effects on ventral tegmental area stimulation reward. Brain Research, 1998, 811, 57-62.	2.2	14
53	Involvement of Î´- and Î¼-opioid receptors in the potentiation of brain-stimulation reward. European Journal of Pharmacology, 1996, 316, 137-143.	3.5	26